Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector

Virology

Volumn 285, Issue 1, 2001, Pages 12-20

  Kovarik, Jiri ^a   Gaillard, Muriel ^a   Martinez, Xavier ^a   Bozzotti, Paola ^a   Lambert, Paul Henri ^a   Wild, T Fabian ^b   Siegrist, Claire Anne ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b INSERM   (France)

Author keywords

CTL; Measles; Murine; Neonates; Th1; Vaccination; Vaccinia vector

Indexed keywords

HEMAGGLUTININ; LIVE VACCINE; MEASLES VACCINE; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; IMMUNIZATION; IMMUNOGENICITY; MEASLES; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; VACCINIA VIRUS; VIRUS ATTENUATION;

ANIMALIA; MEASLES VIRUS; MURINAE; VACCINIA;

EID: 0035919074     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.0945     Document Type: Article

References (40)

1. T-cell function in newborn mice and humans
2. Persistence of maternal antibody in infants beyond 12 months: Mechanism of measles vaccine failure
3. Measles vaccines - A positive step toward eradicating a negative strand
4. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: Predominance of a Th2-biased pattern which persists after adult boosting
5. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype
6. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy
7. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: Protective immune responses in rodents
8. Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus
9. Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses
10. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months
11. IL-12 IFN-gamma, and T cell proliferation to measles in immunized infants
12. Child mortality after high-titre measles vaccines. Prospective study in Senegal
13. The complete DNA sequence of vaccinia virus
14. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria
15. Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: Phenotypic markers that differentiate vaccine and wild-type MV strains
16. DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life
17. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice
18. + T cells using an ELISPOT assay
19. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses
20. Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants
21. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system
22. Successful DNA immunization against measles: Neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles
23. Measles vaccine
24. IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells
25. DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection
26. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies
27. Vaccination in the neonatal period and early infancy
28. Neonatal and early life vaccinology
29. Influence of maternal antibodies on vaccine responses: Inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice
30. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: Influence of adjuvants and maternal antibodies
31. Induction of neonatal TH1 and CTL responses by live viral vaccines: A role for replication patterns within antigen presenting cells?
32. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies
33. Antigenic analysis of current wild type and vaccine strains of measles virus
34. NYVAC: A highly attenuated strain of vaccinia virus
35. Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins
36. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies
37. Measles vaccines, new developments and immunization strategies
38. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice
39. Use of cotton rats for preclinical evaluation of measles vaccines
40. Evaluation of recombinant vaccinia virus-measles vaccines in infant rhesus macaques with preexisting measles antibody